NCT06439576View on ClinicalTrials.gov

Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)

RecruitingOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

May 9, 2024

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions
Diabetic Macular EdemaNeovascular Age-related Macular DegenerationRetinal Vein Occlusion
Interventions
DRUG

Faricimab

The dosing and treatment duration of the studied medicinal product is at the discretion of the physician in accordance with clinical practice and labeling in China.

Trial Locations (6)

200080

RECRUITING

Shanghai General Hospital, Shanghai

265299

RECRUITING

Qingdao Eye Hospital of Shandong First Medical University, Qingdao

430022

RECRUITING

Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology, Wuhan

430030

RECRUITING

Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

Unknown

RECRUITING

Affiliated Hospital of Shandong Second Medical University, Weifang

RECRUITING

Hebei Eye Hospital, Xingtai

All Listed Sponsors
collaborator

Shanghai Roche Pharmaceutical Co., Ltd

UNKNOWN

lead

Hoffmann-La Roche

INDUSTRY